UNIVERSITY^{OF} BIRMINGHAM

University of Birmingham Research at Birmingham

Predictive Biomarkers for Endocrine Therapy

Roseweir, Antonia K; Bennett, Lindsay; Dickson, Ashley; Cheng, Kelvin; Quintayo, Mary-Anne; Bayani, Jane; McMillan, Donald C; Horgan, Paul G; van de Velde, Cornelis J H; Seynaeve, Caroline; Hasenburg, Annette; Kieback, Dirk G; Markopoulos, Christos; Dirix, Luc Y; Rea, Daniel; Mallon, Elizabeth A; Bartlett, John M S; Edwards, Joanne

10.1093/jnci/djx255

License:

Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):

Roseweir, AK, Bennett, L, Dickson, A, Cheng, K, Quintayo, M-A, Bayani, J, McMillan, DC, Horgan, PG, van de Velde, CJH, Seynaeve, C, Hasenburg, A, Kieback, DG, Markopoulos, C, Dirix, LY, Rea, D, Mallon, EA, Bartlett, JMS & Edwards, J 2018, 'Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial', *Journal of the National Cancer Institute*, vol. 110, no. 6, pp. 616-627. https://doi.org/10.1093/jnci/djx255

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

Checked for eligibility: 28/06/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in JNCI: Journal of the National Cancer Institute following peer review. The version of record: Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards; Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial, JNCI: Journal of the National Cancer Institute, Volume 110, Issue 6, 1 June 2018, Pages 616–627 is available online at: https://doi.org/10.1093/jnci/djx255

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

- •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- •User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)

•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.


Take down policy


While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.


If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.


Download date: 25. Apr. 2024




















Study or Subgroup	Exeme: Events		Tamox		Weight	Odds Ratio M-H, Fixed, 95% C	Odds Ratio I M-H, Fixed, 95% CI
1.1.1 ER118	004	4507	007	4570	0.00/	0.00 (0.70 4.40)	
ER118 low	381	1587	397	1570	9.8%	0.93 [0.79, 1.10]	
ER118 high Subtotal (95% CI)	115	550 2137	103	511 2081	2.7% 12.5%	1.05 [0.78, 1.41] 0.96 [0.83, 1.10]	I I
	496	2137	500	2001	12.570	0.50 [0.05, 1.10]	. T
Total events Heterogeneity: Chi ² = 0.44, df = 1 (P = 0.51); I^2 = 0%			500				
Test for overall effect: $Z = 0.59$ (P = 0.56)	0						
1.1.2 ER167	141	E04	162	EEC	4 19/	0.75 (0.59, 0.09)	
ER167 negative ER167 positive	141 342	594 1491	163 342	556 1492	4.1% 8.5%	0.75 [0.58, 0.98] 1.00 [0.84, 1.19]	_
Subtotal (95% CI)	342	2085	342	2048	12.6%	0.92 [0.80, 1.06]	•
Total events	483		505				
Heterogeneity: $Chi^2 = 3.24$, $df = 1$ ($P = 0.07$); $I^2 = 69$ Test for overall effect: $Z = 1.16$ ($P = 0.25$)							
1.1.3 IKK alpha							
IKK alpha negative	183	791	217	788	5.4%	0.79 [0.63, 0.99]	-
IKK alpha positive	150	744	148	701	3.9%	0.94 [0.73, 1.22]	+
Subtotal (95% CI)		1535		1489	9.3%	0.86 [0.72, 1.01]	◆
Total events	333		365				
Heterogeneity: Chi ² = 1.01, df = 1 (P = 0.32); I^2 = 1% Test for overall effect: Z = 1.80 (P = 0.07)	6						
1.1.4 p65 S536							
p65 S536 low	112	422	107	453	2.4%	1.17 [0.86, 1.59]	+
p65 S536 high	362	1623	377	1573	9.6%	0.91 [0.77, 1.07]	+
Subtotal (95% CI)		2045		2026	12.0%	0.96 [0.83, 1.11]	•
Total events	474		484				
Heterogeneity: Chi ² = 1.97, df = 1 (P = 0.16); I^2 = 49 Test for overall effect: Z = 0.51 (P = 0.61)	%						
1.1.5 N-Ras							
N-Ras low	459	1991	470	1961	11.7%	0.95 [0.82, 1.10]	+
N-Ras high	14	48	14	39	0.4%	0.74 [0.30, 1.81]	
Subtotal (95% CI)		2039		2000	12.1%	0.94 [0.82, 1.09]	•
Total events	473		484				
Heterogeneity: Chi ² = 0.30, df = 1 (P = 0.58); I^2 = 0% Test for overall effect: Z = 0.78 (P = 0.44)	6						
1.1.6 Raf-1 338							
Raf 338 negative	352	1390	376	1407	9.0%	0.93 [0.79, 1.10]	+
Raf 338 positive	120	641	104	592	2.8%	1.08 [0.81, 1.44]	<u>†</u>
Subtotal (95% CI)		2031		1999	11.8%	0.97 [0.83, 1.12]	†
Total events	472		480				
Heterogeneity: Chi ² = 0.77, df = 1 (P = 0.38); I^2 = 0% Test for overall effect: Z = 0.46 (P = 0.64)	ó						
1.1.7 p44/42 MAPK 202/204							
p44/42 MAPK 202/204 negative	286	1103	304	1146	7.1%	0.97 [0.80, 1.17]	+
p44/42 MAPK 202/204 positive	188	942	181	864	4.9%	0.94 [0.75, 1.18]	+
Subtotal (95% CI)		2045		2010	12.0%	0.96 [0.83, 1.11]	•
Total events	474		485				
Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); I^2 = 0% Test for overall effect: Z = 0.58 (P = 0.56)	6						
1.1.8 IKK alpha and Raf-1 338							
IKK alpha and Raf 338 both negative	137	570	179	584	4.3%	0.72 [0.55, 0.93]	
IKK alpha and Raf 338 one positive	132	590	122	568	3.1%	1.05 [0.80, 1.39]	l l
IKK alpha and Raf 338 both positive	58	346	58	322	1.6%	0.92 [0.61, 1.37]	,
Subtotal (95% CI)		1506		1474	9.0%	0.87 [0.73, 1.03]	•
Total events	327		359				
Heterogeneity: Chi ² = 4.03, df = 2 (P = 0.13); I^2 = 50 Test for overall effect: Z = 1.62 (P = 0.10)	%						
1.1.9 IKK alpha, Raf-1 338 and ER167							
IKK alpha, Raf 338 and ER167 all negative	41	167	63	172	1.5%	0.56 [0.35, 0.90]	
IKK alpha, Raf 338 and ER167 one/two positive	229	1027	242	1010	6.1%	0.91 [0.74, 1.12]	+
IKK alpha, Raf 338 and ER167 all positive	49	271	44	257	1.2%	1.07 [0.68, 1.67]	
Subtotal (95% CI)		1465		1439	8.8%	0.87 [0.73, 1.04]	•
Total events	319		349				
Heterogeneity: Chi ² = 4.30, df = 2 (P = 0.12); I^2 = 53 Test for overall effect: Z = 1.54 (P = 0.12)	%						
Total (95% CI)		16888		16566	100.0%	0.93 [0.88, 0.98]	•
Total events	3851		4011			•	
Heterogeneity: Chi² = 19.02, df = 19 (P = 0.46); I² =	0%						0.01 0.1 1 10 100
Test for overall effect: Z = 2.90 (P = 0.004)							Favours [exemestane] Favours [tamoxifen]
Test for subgroup differences: Chi ² = 2.94, df = 8 (P	= 0.94),	I ² = 0%					, and a feature of



Positive expression

